{"id":17591,"date":"2025-11-14T16:26:23","date_gmt":"2025-11-14T16:26:23","guid":{"rendered":"https:\/\/lite14.net\/blog\/?p=17591"},"modified":"2025-11-14T16:26:23","modified_gmt":"2025-11-14T16:26:23","slug":"lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention","status":"publish","type":"post","link":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/","title":{"rendered":"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention"},"content":{"rendered":"<p>&nbsp;<\/p>\n<hr \/>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#Full_Details_Lundbecks_Asian_Push_for_Vyepti_Eptinezumab\" >Full Details: Lundbeck\u2019s Asian Push for Vyepti (Eptinezumab)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#My_Assessment_Comments\" >My Assessment &amp; Comments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#Case_Studies_Real-World_Examples\" >Case Studies &amp; Real-World Examples<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#Case_Study_1_SUNRISE_Phase%E2%80%AFIII_Trial_Predominantly_Asian_Population\" >Case Study 1: SUNRISE Phase\u202fIII Trial (Predominantly Asian Population)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#Case_Study_2_Regulatory_Filings_in_Asia_Japan_China_South_Korea\" >Case Study 2: Regulatory Filings in Asia (Japan, China, South Korea)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#Commentary_Strategic_Implications_Risks\" >Commentary, Strategic Implications &amp; Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#My_Assessment\" >My Assessment<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Full_Details_Lundbecks_Asian_Push_for_Vyepti_Eptinezumab\"><\/span>Full Details: Lundbeck\u2019s Asian Push for Vyepti (Eptinezumab)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li><strong>Regulatory Filings Submitted \/ Accepted<\/strong>\n<ul>\n<li>Lundbeck has filed for <strong>marketing authorization<\/strong> of Vyepti (eptinezumab) in <strong>Japan<\/strong>, <strong>China<\/strong>, and <strong>South Korea<\/strong>. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>Specifically, the <strong>New Drug Application (NDA) for Japan<\/strong> has been accepted by Japan\u2019s Ministry of Health, Labor and Welfare (MHLW). (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>These filings are supported by clinical data from the <strong>SUNRISE Phase\u202f3 trial<\/strong>, which focused on a predominantly Asian population. (<a title=\"H. Lundbeck A\/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - Inderes\" href=\"https:\/\/www.inderes.dk\/releases\/h-lundbeck-as-lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyeptir-eptinezumab-for-the-preventive-treatment-of-migraine?utm_source=chatgpt.com\">Inderes<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Why This Is a Big Deal for Lundbeck<\/strong>\n<ul>\n<li>If approved, <strong>it would mark Lundbeck\u2019s first marketing authorization in Japan<\/strong> for Vyepti. (<a title=\"H. Lundbeck A\/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - Inderes\" href=\"https:\/\/www.inderes.dk\/releases\/h-lundbeck-as-lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyeptir-eptinezumab-for-the-preventive-treatment-of-migraine?utm_source=chatgpt.com\">Inderes<\/a>)<\/li>\n<li>It would also represent <strong>Lundbeck\u2019s first biologic launch in China and South Korea<\/strong> \u2014 a significant expansion in its footprint in Asia. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>This move is aligned with Lundbeck\u2019s \u201cFocused Innovator\u201d strategy: they are building their presence in <strong>brain health \/ neurology<\/strong>, and migraine is a key area. (<a title=\"H. Lundbeck A\/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - Inderes\" href=\"https:\/\/www.inderes.dk\/releases\/h-lundbeck-as-lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyeptir-eptinezumab-for-the-preventive-treatment-of-migraine?utm_source=chatgpt.com\">Inderes<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Unmet Need in Asia<\/strong>\n<ul>\n<li>According to Lundbeck, migraine preventive treatments remain <strong>underutilized in East Asia<\/strong>. (<a title=\"H. Lundbeck A\/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.finanznachrichten.de\/nachrichten-2025-11\/66980159-h-lundbeck-a-s-lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-008.htm?utm_source=chatgpt.com\">FinanzNachrichten.de<\/a>)<\/li>\n<li>Lundbeck cites data such as: in Japan, a large proportion of people with migraine have <em>never consulted a physician<\/em>. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>In China, their release notes only a small fraction of adults with migraine are clinically diagnosed. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>So, Lundbeck argues there is a <strong>significant unmet medical need<\/strong> for preventive migraine therapies in these markets. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Clinical Evidence: The SUNRISE Trial<\/strong>\n<ul>\n<li>The <strong>SUNRISE trial (NCT04921384)<\/strong> is a key study in Lundbeck\u2019s authorization strategy: it\u2019s multi-regional, randomized, double\u2011blind, and placebo-controlled. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>In that trial, participants received either eptinezumab (at 100\u202fmg or 300\u202fmg) or placebo via IV infusion. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>The safety profile in SUNRISE was consistent with prior data: common treatment-emergent adverse events included nasopharyngitis, and overall safety was similar to previous eptinezumab trials. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>For Japanese patients, those who completed SUNRISE were offered to continue in the <strong>SUNSET trial<\/strong> (an open-label extension) to assess long-term safety. (<a title=\"H. Lundbeck A\/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - Inderes\" href=\"https:\/\/www.inderes.dk\/releases\/h-lundbeck-as-lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyeptir-eptinezumab-for-the-preventive-treatment-of-migraine?utm_source=chatgpt.com\">Inderes<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>About Vyepti \/ Eptinezumab<\/strong>\n<ul>\n<li>Vyepti is a humanized monoclonal antibody that targets the <strong>calcitonin gene-related peptide (CGRP)<\/strong> pathway. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>It is delivered via <strong>intravenous (IV) infusion<\/strong>, unlike some other anti-CGRP therapies which are subcutaneous. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - PR Newswire APAC\" href=\"https:\/\/en.prnasia.com\/releases\/apac\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-511996.shtml?utm_source=chatgpt.com\">en.prnasia.com<\/a>)<\/li>\n<li>Its clinical development includes <strong>PROMISE-1<\/strong> (episodic migraine) and <strong>PROMISE-2<\/strong> (chronic migraine), both demonstrating reductions in migraine days. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - PR Newswire APAC\" href=\"https:\/\/en.prnasia.com\/releases\/apac\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-511996.shtml?utm_source=chatgpt.com\">en.prnasia.com<\/a>)<\/li>\n<li>The safety data come from a large program (&gt;2,000 patients), and common adverse reactions include nasopharyngitis and hypersensitivity. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>Vyepti is already approved in <strong>over 30 markets<\/strong>. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Strategic Implications for Lundbeck<\/strong>\n<ul>\n<li><strong>Market Expansion<\/strong>: Getting approval in Japan, China, and South Korea would significantly expand Lundbeck\u2019s migraine franchise in large and high-potential markets.<\/li>\n<li><strong>First Biologic in Key Markets<\/strong>: Launching Vyepti in China and South Korea would mark their <strong>first biologic in those markets<\/strong>, which is a major step up in their product sophistication and presence. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li><strong>Addressing Undiagnosed Migraine<\/strong>: By targeting markets where diagnosis and preventive therapy use are low, Lundbeck can tap into a large \u201ctreatment\u2011gap\u201d population \u2014 assuming healthcare systems support uptake.<\/li>\n<li><strong>Neuroscience \/ Brain Health Strategy<\/strong>: This move reinforces Lundbeck\u2019s emphasis on neuroscience and neurological disease, helping position them as a leading innovator in migraine and related CNS (central nervous system) areas.<\/li>\n<li><strong>Regulatory Risk vs Reward<\/strong>: The expedited or successful approval could fast-track revenue growth, but Lundbeck must navigate each country\u2019s complex regulatory landscape (which varies significantly across Asia).<\/li>\n<\/ul>\n<\/li>\n<li><strong>Challenges &amp; Risks<\/strong>\n<ul>\n<li><strong>Regulatory Hurdles<\/strong>: Approvals in Japan, China, and South Korea each require meeting rigorous safety, efficacy, and manufacturing standards.<\/li>\n<li><strong>Reimbursement<\/strong>: Even if approved, pricing and reimbursement could be challenging \u2014 particularly for an IV biologic in competitive or cost-sensitive healthcare markets.<\/li>\n<li><strong>Infrastructure<\/strong>: Administering an IV therapy requires infusion capabilities; in some markets, there may be limited rural or outpatient infusion centers, complicating access.<\/li>\n<li><strong>Physician Awareness<\/strong>: Lundbeck will need to build strong physician education around migraine, diagnosis, and prevention \u2014 especially in markets where migraine is underdiagnosed.<\/li>\n<li><strong>Competition<\/strong>: Other CGRP-targeting drugs (mAbs, gepants) may already be present or entering these markets; Lundbeck will need to differentiate Vyepti clearly.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"My_Assessment_Comments\"><\/span>My Assessment &amp; Comments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Strategically Sound Move<\/strong>: Lundbeck\u2019s filing shows very deliberate expansion. These are <strong>high-impact markets<\/strong>, and success could significantly grow their migraine portfolio.<\/li>\n<li><strong>High Potential, If Executed Well<\/strong>: Given the unmet need (low diagnosis, low use of preventive treatments), Lundbeck has a strong opportunity to make a meaningful difference \u2014 but they must execute on regulatory, access, and education fronts.<\/li>\n<li><strong>Long-Term Value<\/strong>: If they manage to launch Vyepti in Asia successfully, it\u2019s not just a single-product win \u2014 it may pave the way for future neuroscience \/ migraine \/ biologic launches in the region.<\/li>\n<li><strong>Risk Is Elevated, But Reward Justifies It<\/strong>: The costs are significant (regulatory filings, commercialization, infusion infrastructure), but the upside in patient reach and revenue is large.<\/li>\n<li>Good question. While there\u2019s no <strong>public case\u2011study<\/strong> in the classic marketing\u2011case\u2011study sense (i.e., \u201cX percent more patients started treatment because of Lundbeck\u2019s regulatory filings\u201d), there <em>are real clinical and strategic \u201ccase studies\u201d<\/em> in how Lundbeck is executing its Asian push for <strong>Vyepti\u00ae (eptinezumab)<\/strong> \u2014 plus some clear lessons and commentary. Below is a breakdown of those, based on publicly available sources.<br \/>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Case_Studies_Real-World_Examples\"><\/span>Case Studies &amp; Real-World Examples<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Case_Study_1_SUNRISE_Phase%E2%80%AFIII_Trial_Predominantly_Asian_Population\"><\/span><strong>Case Study 1: SUNRISE Phase\u202fIII Trial (Predominantly Asian Population)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>Design &amp; Scope<\/strong>: The <strong>SUNRISE<\/strong> trial (NCT04921384) is a multi\u2011regional, randomized, double-blind, placebo\u2011controlled Phase\u202fIII study with ~983 participants. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - H. Lundbeck A\/S\" href=\"https:\/\/news.cision.com\/h--lundbeck-a-s\/r\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti---eptinezumab--for-th%2Cc4266845?utm_source=chatgpt.com\">Cision News<\/a>)<\/li>\n<li><strong>Population<\/strong>: About 63.5% of the enrolled patients were from Asia (e.g., China, Japan, South Korea). (<a title=\"Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial - PubMed\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41091746\/?utm_source=chatgpt.com\">PubMed<\/a>)<\/li>\n<li><strong>Efficacy Results<\/strong>:\n<ul>\n<li>For weeks 1 to 12, <strong>mean change in monthly migraine days (MMDs)<\/strong> was:\n<ul>\n<li>\u20137.2 days for eptinezumab 100\u202fmg<\/li>\n<li>\u20137.5 days for eptinezumab 300\u202fmg<\/li>\n<li>\u20134.8 days for placebo (<a title=\"Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial - PubMed\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41091746\/?utm_source=chatgpt.com\">PubMed<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li>Both dose arms met the primary endpoint, and key secondary endpoints (\u226550% reduction, \u226575% reduction) also succeeded. (<a title=\"Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti\u00ae (eptinezumab) in migraine prevention\" href=\"https:\/\/www.pharmafocuseurope.com\/pressreleases\/lundbeck-announces-positive-results-from-phase-pivotal-trial?utm_source=chatgpt.com\">Pharma Focus Europe<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Safety<\/strong>: The safety profile in SUNRISE was comparable to placebo: common adverse events included nasopharyngitis. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - H. Lundbeck A\/S\" href=\"https:\/\/news.cision.com\/h--lundbeck-a-s\/r\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti---eptinezumab--for-th%2Cc4266845?utm_source=chatgpt.com\">Cision News<\/a>)<\/li>\n<li><strong>Extension Study<\/strong>: Patients in Japan completing SUNRISE could continue in the <strong>SUNSET trial<\/strong> (open-label, up to 60 weeks) to further assess long-term safety. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - PR Newswire APAC\" href=\"https:\/\/en.prnasia.com\/releases\/apac\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-511996.shtml?utm_source=chatgpt.com\">en.prnasia.com<\/a>)<\/li>\n<\/ul>\n<p><strong>Why This Matters<\/strong>: This is a <em>real-world-anchored case<\/em> \u2014 Lundbeck designed the study to reflect Asian patient populations, addressing both efficacy and safety in the context of the markets where they\u2019re filing for approval. The strong results provide a very solid foundation for regulatory submission in Asia.<\/p>\n<hr \/>\n<h3><span class=\"ez-toc-section\" id=\"Case_Study_2_Regulatory_Filings_in_Asia_Japan_China_South_Korea\"><\/span><strong>Case Study 2: Regulatory Filings in Asia (Japan, China, South Korea)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>Regulatory Milestone<\/strong>: Lundbeck\u2019s New Drug Application (NDA) for Vyepti has been <strong>accepted by Japan\u2019s Ministry of Health, Labor, and Welfare (MHLW)<\/strong>. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li><strong>Parallel Asian Filings<\/strong>: In addition to Japan, Lundbeck has submitted <strong>marketing authorizations for China and South Korea<\/strong>. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li><strong>Strategic Importance<\/strong>:\n<ul>\n<li>If approved, this would be <strong>Lundbeck\u2019s first biologic launch in China and South Korea<\/strong>. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>It also aligns with their \u201cFocused Innovator\u201d R&amp;D \/ growth strategy, especially in <strong>migraine and brain\u2011health \/ neuro\u2011rare<\/strong> disease areas. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine - H. Lundbeck A\/S\" href=\"https:\/\/news.cision.com\/h--lundbeck-a-s\/r\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti---eptinezumab--for-th%2Cc4266845?utm_source=chatgpt.com\">Cision News<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Unmet Need Justification<\/strong>: In their press release, Lundbeck underscores that migraine preventive therapy is <strong>under\u2011utilized in East Asia<\/strong>, citing:\n<ul>\n<li>In Japan, <strong>59\u201372%<\/strong> of migraine sufferers reportedly never consulted a physician. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>In South Korea, the figure is estimated at ~\u202f75.6%. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<li>In China, only ~\u202f13.8% of adults with migraine are clinically diagnosed, per cited data. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<\/ul>\n<\/li>\n<li><strong>Regulatory Rationale<\/strong>: The SUNRISE trial data is explicitly being used to support these NDA submissions. (<a title=\"Lundbeck files for marketing authorization across key Asian markets for Vyepti\u00ae (eptinezumab) for the preventive treatment of migraine\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html?utm_source=chatgpt.com\">PR Newswire<\/a>)<\/li>\n<\/ul>\n<p><strong>Why This Matters<\/strong>: This is a strategic regulatory \u201ccase\u201d: Lundbeck is not just seeking approval \u2014 it\u2019s doing so in a way that directly addresses the <em>market pain points<\/em> (low diagnosis, low preventive therapy usage) with patient data from those same regions.<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Commentary_Strategic_Implications_Risks\"><\/span>Commentary, Strategic Implications &amp; Risks<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Here\u2019s what these case studies reveal, and some broader strategic observations:<\/p>\n<ol>\n<li><strong>Strong Clinical Validation in Target Market<\/strong>\n<ul>\n<li>By running SUNRISE in an Asian-dominant population, Lundbeck avoids a common pitfall: assuming data from Western populations will hold in Asia. The positive efficacy and safety results make their regulatory case much stronger.<\/li>\n<li>The magnitude of MMD reduction (~7+\u202fdays) is clinically meaningful and likely to resonate with both regulators and patients.<\/li>\n<\/ul>\n<\/li>\n<li><strong>High Unmet Need = Big Opportunity<\/strong>\n<ul>\n<li>The numbers Lundbeck cites for underdiagnosis and undertreatment in Asia suggest a <strong>massive underserved population<\/strong>. If approved, Vyepti could capture a real share of a \u201cprevention gap.\u201d<\/li>\n<li>As they point out, many patients may currently rely on acute treatments (e.g., painkillers) and not on preventive biologics \u2014 so there is room for significant growth.<\/li>\n<\/ul>\n<\/li>\n<li><strong>First Mover Advantage in Some Markets<\/strong>\n<ul>\n<li>Launching a <strong>biologic<\/strong> for migraine in China and South Korea could give Lundbeck a strong first-mover \/ early-mover advantage in preventive migraine, depending on local competition.<\/li>\n<li>This could also set the stage for more <strong>neurology \/ brain\u2011health<\/strong> biologics from Lundbeck in Asia, leveraging the infrastructure and regulatory relationships they build now.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Operational Risks<\/strong>\n<ul>\n<li><strong>Regulatory Risk<\/strong>: Even with SUNRISE data, regulators may push for more post\u2011marketing commitments, local cost-effectiveness data, or real-world safety data.<\/li>\n<li><strong>Access \/ Reimbursement Risk<\/strong>: Biologics are expensive; ensuring that eptinezumab is reimbursed (or affordable) in these markets will be critical.<\/li>\n<li><strong>Delivery Risk<\/strong>: Eptinezumab is administered via <strong>IV infusion<\/strong>, which requires infusion infrastructure and patient commitment. In some Asian healthcare contexts, access to infusion centers may be a challenge.<\/li>\n<li><strong>Competition Risk<\/strong>: The CGRP space is competitive; other preventive treatments (antibodies, oral CGRP antagonists) may already exist or be in development locally. Lundbeck will need to differentiate on efficacy, safety, or convenience.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Strategic Upside<\/strong>\n<ul>\n<li>Success could strengthen Lundbeck\u2019s <strong>migraine franchise globally<\/strong> and reinforce its reputation in neuroscience.<\/li>\n<li>It may also help Lundbeck expand more broadly in Asia, not just for migraine but for other neuro-rare or brain-health programs.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"My_Assessment\"><\/span>My Assessment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Overall, very promising<\/strong>: The SUNRISE trial results + regulatory filings form a solid \u201ccase\u201d for Lundbeck\u2019s Asian expansion of Vyepti.<\/li>\n<li><strong>Well-targeted strategy<\/strong>: They are going after high\u2011need markets with real data, not just speculative filings.<\/li>\n<li><strong>Execution is key<\/strong>: The clinical \u201cproof\u201d is there, but Lundbeck\u2019s ability to convert that into <em>market success<\/em> in Asia will depend on regulatory, access, and infrastructure execution.<\/li>\n<li><strong>Medium-to-High Risk, High Reward<\/strong>: If they pull this off, this could be a major boon. But there are non-trivial hurdles, especially around reimbursement and administration.<\/li>\n<\/ul>\n<hr \/>\n<p>&nbsp;<\/li>\n<\/ul>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Full Details: Lundbeck\u2019s Asian Push for Vyepti (Eptinezumab) Regulatory Filings Submitted \/ Accepted Lundbeck has filed for marketing authorization of Vyepti (eptinezumab) in Japan,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[270,90],"tags":[],"class_list":["post-17591","post","type-post","status-publish","format-standard","hentry","category-digital-marketing","category-news-update"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention - Lite14 Tools &amp; Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention - Lite14 Tools &amp; Blog\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Full Details: Lundbeck\u2019s Asian Push for Vyepti (Eptinezumab) Regulatory Filings Submitted \/ Accepted Lundbeck has filed for marketing authorization of Vyepti (eptinezumab) in Japan,...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\" \/>\n<meta property=\"og:site_name\" content=\"Lite14 Tools &amp; Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T16:26:23+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2\"},\"headline\":\"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention\",\"datePublished\":\"2025-11-14T16:26:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\"},\"wordCount\":1676,\"publisher\":{\"@id\":\"https:\/\/lite14.net\/blog\/#organization\"},\"articleSection\":[\"Digital Marketing\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\",\"url\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\",\"name\":\"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention - Lite14 Tools &amp; Blog\",\"isPartOf\":{\"@id\":\"https:\/\/lite14.net\/blog\/#website\"},\"datePublished\":\"2025-11-14T16:26:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lite14.net\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lite14.net\/blog\/#website\",\"url\":\"https:\/\/lite14.net\/blog\/\",\"name\":\"Lite14 Tools &amp; Blog\",\"description\":\"Email Marketing Tools &amp; Digital Marketing Updates\",\"publisher\":{\"@id\":\"https:\/\/lite14.net\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lite14.net\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lite14.net\/blog\/#organization\",\"name\":\"Lite14 Tools &amp; Blog\",\"url\":\"https:\/\/lite14.net\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png\",\"contentUrl\":\"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png\",\"width\":191,\"height\":178,\"caption\":\"Lite14 Tools &amp; Blog\"},\"image\":{\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\/\/lite14.net\/blog\"],\"url\":\"https:\/\/lite14.net\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention - Lite14 Tools &amp; Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/","og_locale":"en_US","og_type":"article","og_title":"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention - Lite14 Tools &amp; Blog","og_description":"&nbsp; Full Details: Lundbeck\u2019s Asian Push for Vyepti (Eptinezumab) Regulatory Filings Submitted \/ Accepted Lundbeck has filed for marketing authorization of Vyepti (eptinezumab) in Japan,...","og_url":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/","og_site_name":"Lite14 Tools &amp; Blog","article_published_time":"2025-11-14T16:26:23+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#article","isPartOf":{"@id":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/"},"author":{"name":"admin","@id":"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2"},"headline":"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention","datePublished":"2025-11-14T16:26:23+00:00","mainEntityOfPage":{"@id":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/"},"wordCount":1676,"publisher":{"@id":"https:\/\/lite14.net\/blog\/#organization"},"articleSection":["Digital Marketing","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/","url":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/","name":"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention - Lite14 Tools &amp; Blog","isPartOf":{"@id":"https:\/\/lite14.net\/blog\/#website"},"datePublished":"2025-11-14T16:26:23+00:00","breadcrumb":{"@id":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lite14.net\/blog\/2025\/11\/14\/lundbeck-seeks-marketing-authorization-in-key-asian-markets-for-vyepti-eptinezumab-for-migraine-prevention\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lite14.net\/blog\/"},{"@type":"ListItem","position":2,"name":"Lundbeck Seeks Marketing Authorization in Key Asian Markets for Vyepti\u00ae (Eptinezumab) for Migraine Prevention"}]},{"@type":"WebSite","@id":"https:\/\/lite14.net\/blog\/#website","url":"https:\/\/lite14.net\/blog\/","name":"Lite14 Tools &amp; Blog","description":"Email Marketing Tools &amp; Digital Marketing Updates","publisher":{"@id":"https:\/\/lite14.net\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lite14.net\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lite14.net\/blog\/#organization","name":"Lite14 Tools &amp; Blog","url":"https:\/\/lite14.net\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png","contentUrl":"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png","width":191,"height":178,"caption":"Lite14 Tools &amp; Blog"},"image":{"@id":"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lite14.net\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/lite14.net\/blog"],"url":"https:\/\/lite14.net\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts\/17591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/comments?post=17591"}],"version-history":[{"count":1,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts\/17591\/revisions"}],"predecessor-version":[{"id":17592,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts\/17591\/revisions\/17592"}],"wp:attachment":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/media?parent=17591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/categories?post=17591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/tags?post=17591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}